A potential approach to treating Crigler-Najjar syndrome is systemic delivery of a gene therapy vector expressing UGT1A1, which would enable the liver to continuously synthesize UGT1A1. This evidence concerns the gene UGT1A1 and Crigler-Najjar syndrome.